---
title: "Minimally-processed cow's milk and early-childhood asthma outcomes — MARTHA randomized trial"
id: "medrxiv-4-minimally-processed-cow-s-milk-and-early-childhood-asthma-related-outcomes"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-4-minimally-processed-cow-s-milk-and-early-childhood-asthma-related-outcomes"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.23.26363903v1?rss=1"
published_at: "2026-10-23T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Minimally-processed cow's milk and early-childhood asthma outcomes — MARTHA randomized trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-4-minimally-processed-cow-s-milk-and-early-childhood-asthma-related-outcomes
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.23.26363903v1?rss=1)
- **Published At:** 2026-10-23T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The MARTHA randomized trial compared **minimally-processed cow's milk** (pasteurized, full-cream) with ultra-heat-treated semi-skimmed milk delivered daily from enrollment at 6–12 months until age 3 years. - Recruitment was centrally randomized and blinded to participants, caregivers, and study staff; however, recruitment stopped early during the SARS-CoV-2 pandemic and the trial continued without confirmatory intention. - The original primary endpoint (composite parent-reported asthma or recurrent obstructive bronchitis to age 5) was formally shifted to **atopic sensitization** at age 3 years after the pandemic-related disruption. - Atopic sensitization occurred in 28 of 99 children in the intervention arm and 24 of 96 in the comparator arm; investigators reported a risk ratio (RR) of 1.13 (0.67–1.89), indicating no reduction with the intervention. - Asthma incidence across the randomized cohort showed an inverse association trend (hazard ratio, HR=0.55 [0.27;1.16], n=252), with a stronger post-hoc signal in 82 children with parental asthma (HR=0.30 [0.09;0.93]). - Post-hoc analyses indicated lower rates of rhinitis and cough in the older half of children assigned to the minimally-processed milk (post-hoc RR=0.82 [0.67–0.998] and RR=0.75 [0.60–0.94], respectively). - No adverse events were judged related to the intervention; safety signals were not observed in the reported data. - Funding sources included Dutch Longfonds, Bavarian State-Ministry of Health, German Center for Lung Research, and FrieslandCampina; competing interests and patent disclosures were reported by several authors. - The trial team concluded the intervention did not reduce **atopic sensitization** at age 3; exploratory results suggest possible protective effects on **asthma** and respiratory symptoms, warranting a definitive trial rather than replacing one.
## Clinical Analysis & Structured Key Points
Minimally processed cow's milk and early childhood asthma-related outcomes: exploratory findings from the early terminated MARTHA randomized trial | medRxiv Skip to main content Minimally processed cow's milk and early childhood asthma-related outcomes: exploratory findings from the early terminated MARTHA randomized trial Melanie Weber , Yvi Huynh , Giulia Pagani , Martin Depner , Silvia Gschwendtner , Hans Demmelmair , Chrysanthi Skevaki , Hermelijn H. Smits , Kasper Hettinga , Michael Schloter , Christine Strunz-Lehner , Joachim Heinrich , Erika von Mutius , View ORCID Profile Markus J. Ege doi: https://doi.org/10.64898/2026.10.23.26363903 Melanie Weber 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yvi Huynh 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Giulia Pagani 2 Helmholtz Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Martin Depner 2 Helmholtz Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Silvia Gschwendtner 2 Helmholtz Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hans Demmelmair 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Chrysanthi Skevaki 3 University of Marburg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hermelijn H. Smits 4 Leiden University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kasper Hettinga 5 Wageningen University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael Schloter 2 Helmholtz Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christine Strunz-Lehner 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joachim Heinrich 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Erika von Mutius 6 LMU Munich; Helmholtz Munich Find this author on Google Scholar Find this author on PubMed Search for this author on this site Markus J. Ege 6 LMU Munich; Helmholtz Munich Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Markus J. Ege For correspondence: markus.ege{at}med.uni-muenchen.de Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background Raw milk consumption has repeatedly been shown to be inversely related to asthma, respiratory infections, and allergies but carries a potential risk of life-threatening infections. The MARTHA trial (DRKS00014781) used minimally-processed pasteurized milk as a microbiologically safe proxy for raw milk and compared it against ultra-heat-treated milk for efficacy on atopic sensitization, asthma, and respiratory infections. Methods Healthy children were recruited through birth clinics in Germany. At 6 to 12 months, they were centrally randomized to obtain minimally-processed full-cream versus ultra-heat-treated semi-skimmed cow's milk daily until age 3 years. During the SARS-CoV-2 pandemic, recruitment was stopped, and the study was continued without confirmatory intention. The primary endpoint was shifted from asthma as composite parent-reported diagnosis of asthma or recurrent obstructive bronchitis until age 5 to atopic sensitization at age 3 years. Participants, caregivers, and study staff were blinded to group assignments. Results We randomized 130 individuals into each study arm. The intervention was unrelated to atopic sensitization (risk ratio, RR=1.13 [0.67-1.89]), which occurred in 28 individuals of the intervention (n=99) and 24 of the comparator group (n=96). Asthma showed a trend for an inverse association (hazards ratio, HR=0.55 [0.27;1.16], n=252), which was pronounced in the 82 children with a family history of asthma (post-hoc HR=0.30 [0.09;0.93]). The intervention was inversely associated with rhinitis and cough in the older half of the children (post-hoc RR=0.82 [0.67-0.998] and RR=0.75 [0.60-0.94], respectively). No adverse events were judged intervention-related. Interpretation The intervention did not reduce atopic sensitization at age 3 years. Exploratory analyses suggested possible protective effects on asthma and respiratory symptoms, particularly in children with parental asthma and in those less affected by pandemic-related disruptions. These findings justify but do not replace a definitive trial. Funding Dutch Longfonds; Bavarian State-Ministry of Health, Care and Prevention; German Center for Lung Research (DZL); FrieslandCampina. Competing Interest Statement HHS reports funding by Dutch Longfonds (Independent investigator-initiated grant). KH reports grants from FrieslandCampina, Danone, Ausnutria; honoraria by Ausnutria; travel support by Mengniu; participation in advisory boards for NewMilkLab, Kate Farms, Tamarack Biotics. EvM reports grants or contracts from Go Bio Initial Grant, BMBF (Federal Ministry of Education and Research), European Research Council Award BEAR Study, O.M. Pharma S.A. Royalties or licenses from Elsevier GmbH, Georg Thieme Verlag, Springer-Verlag GmbH, Elsevier Ltd., Springer Nature Group, Deutscher Apotheker Verlag. Consulting fees from Chinese University of Hongkong, European Commission, AstraZeneca, Imperial College London, OM Pharma S.A., Clarivate. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ALK-Abello Arzneimittel GmbH, Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI), Klinikum Rechts der Isar, University of Colorado, Paul-Martini-Stiftung, Astra Zeneca, BioPharmaceuticals Medical, Imperial College London, Children s Hospital Research Institute of Manitoba, Kompetenzzentrum fuer Ernaehrung (Kern), OM Pharma S.A., Swedish Pediatric Society for Allergy and Lung Medicine, Chinese College of Allergy and Asthma (CCAA), Abbott Laboratories, Deutscher Apotheker Verlag GmbH & Co. KG, Socieded Chilena de Enfermedades Respiratorias, Japanese Society of Allergology, British Society for Asthma and Clinical Immunology, American Academy of Allergy, Asthma & Immunology, European Respiratory Society (ERS), Ludwig Maximilians University Munich, French Health Research Programs Agency, CONSORZIO FUTURO IN RICERCA, Technical University of Munich (TUM), DOC CONGRESS/University of Parma. Support for attending meetings and/or travel from Deutsches Zentrum fuer Lungenforschung (DZL), Fabio Luigi Massimo Ricciardolo/Contatto S.r.l., Fraunhofer ITEM Hannover, MCCA Institut fuer Immunologie Uni Wien, Karl-Landsteiner Privatuniversitaet f. Gesundheitswissenschaften, Swiss Institute of Allergy and Asthma Research (SIAF) Davos (Associated Institute of the University of Zurich), MHH (Medizinische Hochschule Hannover), Natasha Allergy Research Foundation, Deutsche Forschungsgemeinschaft, Gordon Research Conferences, Socieded Chilena de Enfermedades Respiratorias, Arla, Universitaet Leiden, OM Pharma S.A., American Academy of Allergy, Asthma & Clinical Immunology, Deutsche Forschungsgemeinschaft (DFG), European Respiratory Society (ERS), Deutsche Gesellschaft fuer Kinder- und Jugendmedizin, World Allergy Organization (WAO), European Parliament, Gesellschaft fuer Paediatrische Pneumologie (GPP), European Academy of Allergy and Clinical Immunology (EAACI), Helmholtz Association of German Research Centres, Nobel Conference Stockholm, AAA Congress Sarajevo, Karolinska Institutet, Balzan Foundation, Fondazione Menarini, International Union of Immunological Societies (IUIS), Deutsche Gesellschaft fuer Allergologie und klinische Immunologie (DGAKI), Collegium Internationale Allergologicum, European Academy of Allergy & Clinical Immunology (EAACI), Turkish Pediatric Association, University of Parma. Patents planned, issued or pending: EvM has patent No. PCT/EP2019/085016 (Barn dust extract for the prevention and treatment of diseases) issued EU, pending US. Royalties paid to ProtectImmun for patent EP2361632 (Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders, granted on 19 March 2014), and patents EP1411977 (Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases, granted on 18 April 2007), EP1637147 (Stable dust extract for allergy protection, granted on 10 December 2008), and EP 1964570 (Pharmaceutical compound to protect against allergies and inflammatory diseases, granted on 21 November 2012) licensed to ProtectImmun. Patent EP21189353.2. 2021. von Mutius E, Rankl B, Bracher F, Mueller C, Walker A, Hauck SM, Merl-Pham J, inventors; PROTEINS IDENTIFIED FROM BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES. Patent PCT/US2021/016918. 2021. Martinez FD, Vercelli D, Snyder SA, von Mutius E, Pivniouk V, Marques dos Santos M, inventors; THERAPEUTIC FRACTIONS AND PROTEINS FROM ASTHMA-PROTECTIVE FARM DUST. Patent EP21189353.2. 2021. von Mutius E, Rankl B, Bracher F, Mueller C, Walker A, Hauck SM, Merl-Pham J, Adler H, Yildirim A.OE., Sattler M, Santos Dias Mourao A, Borggraefe J, O Connor P.D., Plettenburg O, inventors; PROTEINS IDENTIFIED FROM BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES. Participation on a Data Safety Monitoring Board or Advisory Board: Member of the BEAMS, External Scientific Advisory Board (ESAB), Member of the Editorial Board of The Journal of Allergy and Clinical Immunology: In Practice, Member of the Scientific Advisory Board of the Childrens Respiratory and Environmental Workgroup (CREW), Member of the International Scientific & Societal Advisory Board (ISSAB) of Utrecht Life Sciences (ULS) University of Utrecht, Member of External Review Panel of the Faculty of Veterinary Science, University of Utrecht, Member of the Selection Committee for the Gottfried Wilhelm Leibniz Programme (DFG), Member of the International Advisory Board of The Lancet Respiratory Medicine, Member of the Scientific Advisory Board of the CHILD (Canadian Healthy Infant Longitudinal Development) study, McMaster University, Hamilton, Canada, Member of the Pediatric Scientific Advisory Board Iceland, Member of the Abbott Allergy Risk Reduction Advisory Board, Member of the HpVac Scientific Advisory Board, Member of the OM Pharma Scientific Advisory Board, Member of the Award Committee of the International Balzan Foundation, Member of the Scientific Advisory Board for French Prevention National Research Programme, Member of the Scientific Advisory Panel for The Natasha Allergy Research Foundation. MJE reports funding by the German Center for Lung Resarch (DZL), Dutch Longfonds Patient Organization (research funding, travel grant), International Milk Genomics Consortium (travel grant), Friesland Campina (milk powder for pilot phase). All other authors do not report potential conflicts of interest. Clinical Trial DRKS00014781 Clinical Protocols https://www.drks.de/search/de/trial/DRKS00014781/details Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study and all changes were approved by the ethics committee at the Medical Faculty of LMU Munich (18-0405). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data can be analyzed on the protected platform TRACE upon application.The R code of the original analysis can be found in the supplemental material. https://trace.ibe.med.uni-muenchen.de/ https://www.ebi.ac.uk/ena/browser/home Funder Information Declared Dutch Longfonds , AWWA Consortium Bavarian State Ministry for Health, Care, and Prevention , URS FrieslandCampina (Netherlands), https://ror.org/025mtxh67 , milk powder (pilot phase) German Center for Lung Research, https://ror.org/03dx11k66 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted October 23, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Minimally processed cow's milk and early childhood asthma-related outcomes: exploratory findings from the early terminated MARTHA randomized trial Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Minimally processed cow's milk and early childhood asthma-related outcomes: exploratory findings from the early terminated MARTHA randomized trial Melanie Weber , Yvi Huynh , Giulia Pagani , Martin Depner , Silvia Gschwendtner , Hans Demmelmair , Chrysanthi Skevaki , Hermelijn H. Smits , Kasper Hettinga , Michael Schloter , Christine Strunz-Lehner , Joachim Heinrich , Erika von Mutius , Markus J. Ege medRxiv 2026.10.23.26363903; doi: https://doi.org/10.64898/2026.10.23.26363903 Share This Article: Copy Citation Tools Minimally processed cow's milk and early childhood asthma-related outcomes: exploratory findings from the early terminated MARTHA randomized trial Melanie Weber , Yvi Huynh , Giulia Pagani , Martin Depner , Silvia Gschwendtner , Hans Demmelmair , Chrysanthi Skevaki , Hermelijn H. Smits , Kasper Hettinga , Michael Schloter , Christine Strunz-Lehner , Joachim Heinrich , Erika von Mutius , Markus J. Ege medRxiv 2026.10.23.26363903; doi: https://doi.org/10.64898/2026.10.23.26363903 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (634) Allergy and Immunology (914) Anesthesia (347) Cardiovascular Medicine (4944) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (672) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1667) Epidemiology (16164) Forensic Medicine (35) Gastroenterology (1236) Genetic and Genomic Medicine (7213) Geriatric Medicine (747) Health Economics (1091) Health Informatics (5225) Health Policy (1456) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16428) Intensive Care and Critical Care Medicine (1192) Medical Education (691) Medical Ethics (156) Nephrology (739) Neurology (7500) Nursing (375) Nutrition (1114) Obstetrics and Gynecology (1281) Occupational and Environmental Health (1031) Oncology (3709) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (493) Palliative Medicine (142) Pathology (717) Pediatrics (1844) Pharmacology and Therapeutics (749) Primary Care Research (781) Psychiatry and Clinical Psychology (6065) Public and Global Health (9916) Radiology and Imaging (2499) Rehabilitation Medicine and Physical Therapy (1500) Respiratory Medicine (1263) Rheumatology (656) Sexual and Reproductive Health (794) Sports Medicine (594) Surgery (795) Toxicology (109) Transplantation (315) Urology (303)
## Related Clinical Research

- [Congenital anomalies, deprivation, and long-term health conditions linked to lower school attainme](https://medichelpline.com/clinical-feed/plos-medicine-0-associations-of-major-congenital-anomalies-long-term-health-conditions-and.md)
- [Age-Dependent Differences in Disease Risk for People with Down Syndrome](https://medichelpline.com/clinical-feed/medrxiv-14-effects-of-age-on-the-association-between-down-syndrome-and-common-disease.md)
- [BMI Trajectories From Birth to Adolescence and Their Association With Asthma in the Leicester Coho](https://medichelpline.com/clinical-feed/medrxiv-18-body-mass-index-trajectories-from-birth-to-adolescence-and-their-association.md)
- [Olive oil before carbs and blood sugar: what the mouse study found](https://medichelpline.com/clinical-feed/medical-news-today-0-olive-oil-shot-trend-what-science-really-says-about-fat-and-glucose-response.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.